Loading...
Market
What will be the total sales of Zunveyl in China in the first year post-launch?
2
Resolution / Starting Odds
Less than $10 million • 25%
$10 million to $20 million • 25%
$20 million to $30 million • 25%
More than $30 million • 25%
Financial reports from Alpha Cognition or China Medical System
Story
Alpha Cognition Secures $44 Million Licensing Deal for Alzheimer's Drug Zunveyl in China, Including $6 Million Upfront
Jan 8, 2025, 01:48 PM
Alpha Cognition Inc. has announced a $44 million exclusive licensing agreement for the development and commercialization of Zunveyl, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, in China. The deal includes a $6 million upfront payment and covers regions including Asia (excluding Japan), Australia, and New Zealand. Zunveyl, also known as benzgalantamine, is anticipated to address neuroinflammation associated with Alzheimer’s disease. This agreement was made with China Medical System, as Alpha Cognition aims to expand its market presence in the Asia-Pacific region.
View original story
Similar markets
More than $300 million • 25%
$100 million to $200 million • 25%
Less than $100 million • 25%
$201 million to $300 million • 25%
Above 15 million units • 25%
Below 9 million units • 25%
12 to 15 million units • 25%
9 to 11.9 million units • 25%
14-15 million • 25%
Over 15 million • 25%
13-14 million • 25%
12-13 million • 25%
$2 billion to $3 billion • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
More than $3 billion • 25%